24% of patients will wait 5 months or more to get a myeloma diagnosis

MPE, MyelomaLeave a comment

Today is European Myeloma Day, a date to raise awareness about the most important issues for European myeloma patients. The findings of a recent report developed by Myeloma Patients Europe (MPE) are the driving reason for early diagnosis to be the focus of European Myeloma Day this year. By raising awareness of myeloma and disseminating an important tool called Myeloma Diagnosis Pathway, the myeloma patient community aims to improve early diagnosis and therefore patients’ lives.…

MPE attending International Myeloma Society (IMS) Annual Meeting in Athens

MPE, NewsLeave a comment

Myeloma Patients Europe (MPE) is attending the International Myeloma Society (IMS) Annual Meeting in Athens, Greece, from 27 – 30 September. This year, the IMS meeting corresponds with European Myeloma Day, allowing us to engage with the whole myeloma community to mark this important event.   The IMS Annual Meeting brings together myeloma experts from research, nursing, clinical and patient advocacy backgrounds to discuss the latest knowledge and developments in the field. It is a…

Job Offer – Access and Policy Manager

MPELeave a comment

Job Title: Access and Policy Manager Position Type: Full time/permanent  Location: Home-based in Belgium, UK, Germany, France or Spain. Other locations in the EU would be considered depending on experience Travel required: 30 days / year (approx.) Gross salary range: 40.000 – 50.000 EUR/year (35.000-45.000 GBP/year)   If you wish to apply or have any questions, please send an email to  with a cover letter and CV.   As Access and Policy Project Manager, you will work…

Horizon2020 CARAMBA CAR-T interview series

CAR-T, MPELeave a comment

From T-cell collection to CAR T-cell infusion Myeloma Patients Europe (MPE) has conducted four written interviews on CAR-T manufacturing to better understand various myeloma CAR-T therapies’ manufacturing processes and challenges. Four stakeholders have answered our questions, including two pharmaceutical companies, each with a myeloma CAR-T product approved in the European Union, and two academic teams which have developed myeloma CAR-T products currently under clinical investigation.       Interview of Janssen Pharmaceuticals on their CAR T-cell manufacturing process…

Sign up for the MPE webinar on EHA myeloma and AL amyloidosis highlights 

AL amyloidosis, Conferences, MPE, MyelomaLeave a comment

Myeloma Patients Europe (MPE) will host a webinar to summarise the most important myeloma and AL amyloidosis updates presented at the congress on 6 July 2023, from 17:00 – 18:00 CET, given by Prof. Dr. Mohamad Mohty, Professor and Head of the Hematology and cellular therapy department at the Saint-Antoine Hospital and Sorbonne University (Paris, France).   If you would like to attend, click here and register now!   The European Hematology Association (EHA) 2023 hybrid congress took place from…

Myeloma Patients Europe appoints joint CEOs

MPELeave a comment

Myeloma Patients Europe (MPE) is pleased to announce that Katie Joyner and Kate Morgan have been appointed as joint Chief Executive Officers (CEO). The MPE Board of Directors unanimously made this decision based on the impressive work and leadership both have shown during the transition period following the stepping down of founding CEO, Ananda Plate.

Picture of the awards given at the AMILO conference

Happy anniversary AMILO!

MPELeave a comment

One of the MPE Spanish members, the Spanish Amyloidosis Association (AMILO), last month celebrated its fifth anniversary by recognising the support and help other organisations have given them during these five years. MPE is pleased and proud to receive this recognition from AMILO at such an important event for our member. Along with MPE, other important national and international organisations were awarded, like the Amyloidosis Alliance and the Spanish Society of Hematology, represented by its…